Arbutus Biopharma Corp Stock Analysis

Arbutus Stock Analysis Notes

About 22.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.43. Arbutus Biopharma Corp had not issued any dividends in recent years. The entity had 1:5 split on the 4th of November 2010. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus infection, SARS-CoV-2, and other coronaviruses in the United States. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Arbutus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people. For more info on Arbutus Biopharma Corp please contact William Collier at 267 469 0914 or go to https://www.arbutusbio.com.

Arbutus Biopharma Corp Investment Alerts

Arbutus Biopharma Corp Upcoming and Recent Events

Arbutus Largest EPS Surprises

View All Earnings Estimates

Arbutus Biopharma Environmental, Social, and Governance (ESG) Scores

Arbutus Stock Institutional Investors

Note, although Arbutus Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arbutus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 626.26 M.

Arbutus Profitablity

Management Efficiency

Arbutus Biopharma Corp has return on total asset (ROA) of (0.3283) % which means that it has lost $0.3283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6781) %, meaning that it created substantial loss on money invested by shareholders. Arbutus Biopharma's management efficiency ratios could be used to measure how well Arbutus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2025. Return On Capital Employed is likely to drop to -0.61 in 2025. At this time, Arbutus Biopharma's Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 165.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 13.5 M in 2025.

Technical Drivers

As of the 23rd of March, Arbutus Biopharma shows the risk adjusted performance of (0.01), and Mean Deviation of 1.96. Arbutus Biopharma Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Arbutus Biopharma Corp risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Arbutus Biopharma Corp is priced correctly, providing market reflects its regular price of 3.28 per share. Given that Arbutus Biopharma has information ratio of 8.0E-4, we suggest you to validate Arbutus Biopharma Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Arbutus Biopharma Corp Price Movement Analysis

Arbutus Biopharma Corp Insider Trading Activities

Arbutus Biopharma Outstanding Bonds

Arbutus Biopharma Predictive Daily Indicators

Arbutus Biopharma Corporate Filings

Arbutus Biopharma Forecast Models

Arbutus Biopharma's time-series forecasting models are one of many Arbutus Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arbutus Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arbutus Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arbutus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Arbutus Biopharma. By using and applying Arbutus Stock analysis, traders can create a robust methodology for identifying Arbutus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arbutus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arbutus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Arbutus Biopharma Corp stock analysis indicators help investors evaluate how Arbutus Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arbutus Biopharma shares will generate the highest return on investment. By understating and applying Arbutus Biopharma stock analysis, traders can identify Arbutus Biopharma position entry and exit signals to maximize returns.

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.